Alternative in Beta Blocker Intolerance: The ABBI Trial
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in
cardiovascular patients who are not able to tolerate conventional beta blockers. A side
effect profile will be tracked and compared with previous beta blocker use.
The investigators hypothesize that Bystolic will be tolerated by many patients who are
intolerant of conventional blockers.